Pharmacological Inhibition of Acid Sphingomyelinase Ameliorates Experimental Autoimmune Encephalomyelitis.

CONCLUSION: The studies identify the acid sphingomyelinase as a novel therapeutic target for treating MS patients.
PMID: 31778303 [PubMed - in process]

Source: Neuro-Signals - December 1, 2019 Category: Neurology Authors: Walter S, Gulbins E, Halmer R, Jahromi NH, Becker KA, Schottek A, Blatti C, Davies L, Schnoeder L, Bertsch T, Engelhardt B, Fassbender K Tags: Neurosignals Source Type: research